Skip to main content

Table 3 Baseline characteristics in belatacept cohort by status for treatment success or failure censored for death. Treatment failure was defined as graft failure or GFR deterioration compared to the time of conversion

From: Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept

Patient characteristics All patients (N = 30) Treatment success at 12 months (N = 16) Treatment failure at 12 months (N = 13) P value Treatment success at 24 months (N = 12) Treatment failure at 24 months (N = 15) P value
Age (y) 53.5 ± 26 53.5 ± 26 50 ± 29 0.983 52 ± 18 50 ± 30 0.829
Donor age (y) 48 ± 23 46.5 ± 31 46 ± 22 0.689 43 ± 26 52.5 ± 23 0.134
Gender (m/f) 20/10 11/5 8/5 0.714 10/2 7/8 0.107
Post-transplant diabetes 3/30 2/16 1/13 1.000 1/12 2/15 1.000
BMI 25.3 ± 4.1 24.7 ± 4.0 25.5 ± 6.1 0.650 24.7 ± 4.0 25.3 ± 7.9 0.100
Systolic BP (mmHg) 134 ± 17 139 ± 24 133 ± 18 0.199 139 ± 27 132 ± 14 0.183
Diastolic BP (mmHg) 84 ± 10 85 ± 10 84 ± 12 0.812 88.5 ± 12 83 ± 13 0.300
Time after transplantation (m) 127.5 ± 91.3 128.5 ± 148.8 127 ± 60 0.619 133.5 ± 125.8 126 ± 74 0.300
eGFR (mL/min) 22.5 ± 12 25 ± 12 20 ± 10 0.449 25.5 ± 14 20.0 ± 12 0.126
eGFR < 25 mL/min 17/30 7/16 10/13 0.130 5/12 11/15 0.130
Proteinuria (mg/g creatinine) 840 ± 1166 647 ± 1125 890 ± 1857 0.398 452 ± 1125 869 ± 1592 0.399
Living donor transplants 8/30 3/16 5/13 0.406 3/12 4/15 1.000
pancreas/kidney 2/30    
Immunosuppression
 Tacrolimus 22/30 12/4 9/4 1.000 9/12 10/15 0.696
 Cyclosporine A 8/30 4/12 4/9 1.000 3/12 5/15 0.696
 Mycophenolic acid 27/30 13/3 13/0 0.232 10/12 15/15 0.188
 Azathioprin 2/30 2/14 0/13 0.488 1/12 0/15 0.444
 Steroid 24/30 13/3 10/3 1.000 10/12 11/15 0.662
DSA 14/30 7/16 6/13 1.000 5/12 7/15 1.000
h/o any rejection 15/30 6/16 9/13 0.139 6/12 8/15 1.000
aTCMR 3/30 1/16 2/13 0.573 1/12 2/15 1.000
aABMR 6/30 1/16 5/13 0.064 1/12 5/15 0.182
Biopsy scores
 Glomerular scarring (%) 30.5 ± 33 26 ± 29 32 ± 35.5 0.423 27 ± 33 32 ± 36 0.829
 Cg 0.0 ± 3.0 0.0 ± 2.6 1.0 ± 3.0 0.288 0.0 ± 1.1 1.0 ± 3.0 0.236
 ct 1.0 ± 1.0 1.0 ± 1.0 1.0 ± 2.0 0.983 1.0 ± 1.0 1.0 ± 1.0 0.548
 ci 1.0 ± 1.0 1.0 ± 1.0 1.0 ± 1.0 0.846 1.0 ± 1.0 1.0 ± 1.0 0.683
 cv 2.0 ± 2.0 2.0 ± 2.0 2.0 ± 2.0 0.339 2.0 ± 3.0 2.0 ± 1.0 0.959
 mm 1.0 ± 2.0 0.0 ± 1.8 1.0 ± 1.5 0.170 0.0 ± 1.8 1.0 ± 2.0 0.373
 ah 3.0 ± 0.0 3.0 ± 0.0 3.0 ± 0.5 0.650 3.0 ± 0.4 3.0 ± 0.0 0.581
 g 0.0 ± 1.0 0.0 ± 0.8 0.0 ± 1.8 0.589 0.0 ± 0.8 0.0 ± 1.5 0.581
 t 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 1.0 0.589 0.0 ± 0.0 0.0 ± 0.0 0.829
 i 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 1.0 0.156 0.0 ± 0.0 0.0 ± 0.0 0.905
 v 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 1.000 0.0 ± 0.0 0.0 ± 0.0 1.000
 ptc 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 2.0 0.170 0.0 ± 0.0 0.0 ± 1.0 0.256
 C4d 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.948 0.0 ± 0.0 0.0 ± 0.0 0.981
 MVI sum score 0.0 ± 1.3 0.0 ± 0.8 0.0 ± 2.8 0.144 0.0 ± 0.8 0.0 ± 2.5 0.183
 MVI sum score 2 7/30 1/16 6/13 0.026 1/12 6/15 0.091
  1. Data were expressed as medians (interquartile range), or numbers
  2. BMI body mass index, BP blood pressure, eGFR estimated glomerular filtration rate, DSA donor specific antibodies, h/o history of, aTCMR active T cell mediated rejection, aABMR active antibody-mediated rejection, MVI microvascular inflammation